SERCA Inhibition by BHQ Enhances Hematopoietic Stem Cell Mob
2026-04-20
Li et al. (2025) demonstrate that inhibiting SERCA with 2,5-di-tert-butylbenzene-1,4-diol (BHQ) induces mild endoplasmic reticulum stress and significantly improves hematopoietic stem cell (HSC) mobilization via the CaMKII-STAT3-CXCR4 axis. These findings highlight a promising mechanistic strategy for optimizing HSC collection in transplantation protocols.
Tioconazole in Antifungal Drug Development: Workflows & Insi
2026-04-19
Tioconazole empowers antifungal research with high-purity, validated performance and versatile solubility, streamlining both in vitro assays and fungal infection modeling. This article delivers actionable experimental workflows, troubleshooting strategies, and evidence-based protocol enhancements for advanced antifungal drug development.
Radicicol: Hsp90 Inhibitor for Apoptosis, Adipogenesis & Sep
2026-04-18
Radicicol is a potent Hsp90 inhibitor with distinctive multi-pathway effects on apoptosis, adipogenesis, and inflammation. Its robust, quantified inhibition profile and protocol flexibility make it a premier choice for advanced experimental designs in cancer, obesity, and immune modulation research.
Talin1–Piezo1–YAP Axis Drives Endothelial Inflammation in At
2026-04-17
This study identifies Talin1 as a key mediator linking mechanical and inflammatory cues to endothelial activation in atherosclerosis. By dissecting the Piezo1–YAP signaling pathway, the research highlights novel intervention points for modulating vascular inflammation and plaque development.
Bufalin Targets STK33 to Suppress Triple-Negative Breast Can
2026-04-16
This study identifies Serine/Threonine Kinase 33 (STK33) as a novel binding partner and degradation target of Bufalin in triple-negative breast cancer (TNBC). By disrupting the STK33-HSP90 complex and promoting STK33 degradation, Bufalin inhibits TNBC cell proliferation, suggesting a promising therapeutic avenue for this challenging cancer subtype.
Precision Protein Quantification: Empowering BBB Research
2026-04-15
This thought-leadership article explores how highly sensitive, mechanistically robust protein quantification—anchored by the APExBIO BCA Protein Assay Kit—enables translational neuroscientists to unravel and therapeutically target blood–brain barrier disruption in HIV-associated neurocognitive disorder (HAND). Drawing from recent advances in endothelial pyroptosis research and integrating competitive benchmarking, this guide offers actionable insights for experimental rigor and workflow optimization.
Dabigatran Etexilate: Shifting the Paradigm in Oral Anticoag
2026-04-14
Dabigatran etexilate represents a significant advance in oral anticoagulation, offering predictable pharmacokinetics and efficacy in venous thromboembolism (VTE) and stroke prevention without reliance on the cytochrome P450 system. This review underscores its clinical impact and implications for drug-drug interaction studies, especially contrasting with CYP3A-metabolized agents.
HotStart Universal 2X FAST Green qPCR Master Mix in Hormone-
2026-04-13
Explore how HotStart Universal 2X FAST Green qPCR Master Mix enables rapid, specific, and reproducible qPCR for hormone-signaling gene expression studies. This article reveals unique assay strategies and practical insights, grounded in recent transcriptomic research.
Viral vIRD-Mediated RIPK3 Degradation Modulates Necroptosis
2026-04-12
Liu et al. identify a viral protein class (vIRD) in orthopoxviruses that targets the necroptosis adaptor RIPK3 for proteasomal degradation, thereby regulating virus-induced inflammation and pathogenesis. This mechanistic insight advances our understanding of host–pathogen interactions and the evolutionary arms race between viral evasion strategies and innate immunity.
Calnexin-Dependent Rescue of CFTR Variants: Insights for CF
2026-04-12
This study systematically profiles how calnexin modulates the expression and pharmacological rescue of over 200 CFTR variants, revealing critical dependencies that shape the efficacy of corrector molecules such as VX-661. The findings advance understanding of proteostasis in cystic fibrosis and inform variant-specific therapeutic development.
BX795: A Potent PDK1 Inhibitor for Quantitative Assay Design
2026-04-11
BX795 enables precision targeting of PDK1, TBK1, and IKKε, empowering advanced in vitro workflows for cancer biology and innate immune modulation. This article translates recent in vitro methodology advances into actionable protocols, troubleshooting strategies, and optimized experimental designs for researchers seeking reliable kinase pathway inhibition.
Lipid Peroxidation (MDA) Assay Kit: Optimizing Oxidative Str
2026-04-11
The Lipid Peroxidation (MDA) Assay Kit enables robust, sensitive malondialdehyde quantification across diverse sample types, leveraging colorimetric and fluorescence modalities for unparalleled versatility. Discover advanced workflow strategies, real troubleshooting tips, and translational insights rooted in state-of-the-art ferroptosis research.
Perphenazine: Dopamine D2 Antagonist for Neuropharmacolog...
2026-04-10
Perphenazine is an intermediate-potency dopamine D2 receptor antagonist with a verified multi-receptor binding profile, supporting research in schizophrenia, psychosis, and mitochondria-mediated cell death. Recent evidence highlights its role in immunomodulation, including macrophage activation and host-directed antibacterial responses. This dossier synthesizes mechanistic details, benchmarks, and workflow parameters for reproducible experimentation.
Perphenazine: Dopamine D2 Antagonist for Neuropharmacolog...
2026-04-09
Perphenazine is a dopamine D2 receptor antagonist with well-characterized multi-receptor binding, validated as both a neuropharmacology research tool and a modulator of mitochondria-mediated cell death. It demonstrates robust suppression of opioid tolerance and enhances antibacterial defense via host-directed mechanisms. This dossier details its atomic pharmacological properties and research applications, supporting reproducible workflows.
Perphenazine: Dopamine D2 Antagonist for Neuropharmacolog...
2026-04-08
Perphenazine stands out as a dopamine D2 receptor antagonist with potent effects in both neuropharmacology and host-pathogen research, enabling advanced modeling of schizophrenia, psychosis, and mitochondrial cell death. Its multi-receptor activity and proven role in immune modulation and opioid tolerance suppression make it a critical tool for innovative, reproducible bench workflows.
466 records 22/32 page Previous Next First page 上5页 2122232425 下5页 Last page